维普中文期刊产品整合服务
125篇 您的检索式:作者名="Yuji Watanabe"
    题名 作者 年代 出处 被引量
1烧结工艺使用气体燃料喷入技术减少CO_2排放显示文摘JFE钢铁公司开发了在烧结矿表面喷入含氢的气体燃料技术,可不增加焦粉配比,提高烧结矿质量。使用该技术,含氢气体可部分替代焦粉,使1200~1400℃的燃烧层变宽成为可能。通过X射线对多孔状的烧结饼进行CT检查与烧结锅试验,从理论到实践都证明了喷入燃料气体技术的使用效果。保持1200~1400℃的温度带,为生产高强度、高还原性的烧结矿至关重要,它能使合适的温度带变宽、液相率增加、提高1~5mm孔隙间的熔合并提升烧结矿强度。大于5mm的孔隙的烧结矿数量增多提高了料层的透气性,低温烧结工艺也抑制了铁矿石的自身熔化。而在未熔化的铁矿石中,小于1μm的微孔隙的存在也使烧结矿的还原性提高,从而改善烧结饼的孔隙结构,提高烧结矿质量。2009年1月,京浜1号烧结机应用了该技术,到目前为止工况稳定。结果,烧结工序的能源利用率大幅提升,减排CO2约6万t/a。Nobuyuki Oyama Yuji Iwami Satoshi Machida Takahide Higuchi Tetsuya Yamamoto Yushinori Watanabe Michitaka Sato Kanji Takeda Masakata Shimizu Koki Nishioka 何海良 2013世界钢铁2013,,1:11
2Current status of preoperative drainage for distal biliary obstruction显示文摘Preoperative biliary drainage(PBD) was developed to improve obstructive jaundice, which affects a number of organs and physiological mechanisms in patients waiting for surgery. However, its role in patients who will undergo pancreaticoduodenectomy for biliary obstruction remains controversial. This article aims to review the current status of the use of preoperative drainage for distal biliary obstruction. Relevant articles published from 1980 to 2015 were identified by searching MEDLINE and Pub Med using the keywords 'PBD', 'pancreaticoduodenectomy', and 'obstructive jaundice'. Additional papers were identified by a manual search of the references from key articles. Current studies have demonstrated that PBD should not be routinely performed because of the postoperative complications. PBD should only be considered in carefully selected patients, particularly in cases where surgery had to be delayed. PBD may be needed in patients with severe jaundice, concomitant cholangitis, or severe malnutrition. The optimal method of biliary drainage has yet to be confirmed. PBD should be performed by endoscopic routes rather than by percutaneous routes to avoid metastatic tumor seeding. Endoscopic stenting or nasobiliary drainage can be selected. Although more expensive, the use of metallic stents remains a viable option to achieve effective drainage without cholangitis and reintervention.Harutoshi Sugiyama Toshio Tsuyuguchi Yuji Sakai Rintaro Mikata Shin Yasui Yuto Watanabe Dai Sakamoto Masato Nakamura Reina Sasaki Jun-ichi Senoo Yuko Kusakabe Masahiro Hayashi Osamu Yokosuka 2015World Journal of Hepatology2015,7,18:11
3Short-and long-term results of endoscopic ultrasoundguided transmural drainage for pancreatic pseudocysts and walled-off necrosis显示文摘AIM To evaluate the short-and long-term results of endoscopic ultrasound-guided transmural drainage(EUS-GTD) for pancreatic fluid collection(PFC) and identify the predictive factors of treatment outcome for walled-off necrosis(WON) managed by EUS-GTD alone.METHODS We investigated 103 consecutive patients with PFC who underwent EUS-GTD between September 1999 and August 2015. Patients were divided into four groups as follows: WON(n = 40), pancreatic pseudocyst(PPC; n = 11), chronic pseudocyst(n = 33), and others(n = 19). We evaluated the short-and long-term outcomes of the treatment. In cases of WON, multiple logistic regression analyses were performed to identify the predictor variables associated with the treatment success. In addition, PFC recurrence was examined in patients followed up for more than 6 mo and internal stent removal after successful EUS-GTD was confirmed.RESULTS In this study, the total technical success rate was 96.1%. The treatment success rate of WON, PPC, chronic pseudocyst, and others was 57.5%, 90.9%, 91.0%, and 89.5%, respectively. Contrast-enhanced computed tomography using the multivariate logistic regression analysis revealed that the treatment success rate of WON was significantly lower in patients with more than 50% pancreatic parenchymal necrosis(OR = 17.0; 95%CI: 1.9-150.7; P = 0.011) and in patients with more than 150 mm of PFC(OR = 27.9; 95%CI: 3.4-227.7; P = 0.002).The recurrence of PFC in the long term was 13.3%(median observation time, 38.8 mo). Mean amylase level in the cavity was significantly higher in the recurrence group than in the no recurrence group(P = 0.02).CONCLUSION The reduction of WON by EUS-GTD alone was associated with the proportion of necrotic tissue and extent of the cavity. The amylase level in the cavity may be a predictive factor for recurrence of PFC.Yuto Watanabe Rintaro Mikata Shin Yasui Hiroshi Ohyama Harutoshi Sugiyama Yuji Sakai Toshio Tsuyuguchi Naoya Kato 2017World Journal of Gastroenterology2017,23,39:7
4En bloc pancreaticoduodenectomy and right hemicolectomy for locally advanced right-sided colon cancer显示文摘AIM To assess the usefulness of en bloc right hemicolectomy with pancreaticoduodenectomy(RHCPD) for locally advanced right-sided colon cancer(LARCC).METHODS We retrospectively reviewed the database of Saitama Medical Center, Jichi Medical University, between January 2009 and December 2016. During this time, 299 patients underwent radical right hemicolectomy for right-sided colon cancer. Among them, 5 underwent RHCPD for LARCC with tumor infiltration to adjacent organs. Preoperative computed tomography(CT) was routinely performed to evaluate local tumor infiltration into adjacent organs. During the operation, we evaluated the resectability and the amount of infiltration into the adjacent organs without dissecting the adherent organs from the cancer. When we confirmed that radical resection was feasible and could lead to R0 resection, we performed RHCPD. The clinical data were carefully reviewed, and the demographic variables, intraoperative data, and postoperative parameters were recorded.RESULTS The median age of the 5 patients who underwent RHCPD for LARCC was 70 years. The tumors were located in the ascending colon(three patients) and transverse colon(two patients). Preoperative CT revealed infiltration of the tumor into the duodenum in all patients, the pancreas in four patients, the superior mesenteric vein(SMV) in two patients, and tumor thrombosis in the SMV in one patient. We performed RHCPD plus SMV resection in three patients. Major postoperative complications occurred in 3 patients(60%) as pancreatic fistula(grade B and grade C, according to International Study Group on Pancreatic Fistula Definition) and delayed gastric empty. None of the patients died during their hospital stay. A histological examination confirmed malignant infiltration into the duodenum and/or pancreas in 4 patients(80%), and no patients showed any malignant infiltration into the SMV. Two patients were histologically confirmed to have tumor thrombosis in the SMV. All of the tumors had clear resection margins(R0). The median follow-up time was 77 mo. During this period, two patients with tumor thrombosis died from liver metastasis. The overall survival rates were 80% at 1 year and 60% at 5 years. All patients with node-negative status(n = 2) survived for more than seven years.CONCLUSION This study showed that the long-term survival is possible for patients with LARCC if RHCPD is performed successfully, particularly in those with node-negative status.Yuji Kaneda Hiroshi Noda Yuhei Endo Nao Kakizawa Kosuke Ichida Fumiaki Watanabe Takaharu Kato Yasuyuki Miyakura Koichi Suzuki Toshiki Rikiyama 2017World Journal of Gastrointestinal Oncology2017,9,9:4
5Endoscopic papillary large balloon dilation for bile duct stones in elderly patients显示文摘AIM: To investigate whether endoscopic papillary large balloon dilation(EPLBD) can be safety and effectively performed in patients aged ≥ 80 years. METHODS: Lithotomy by EPLBD was conducted in 106 patients with bile duct stones ≥ 13 mm in size or with three or more bile duct stones ≥ 10 mm. The patients were divided into group A(< 80 years) and group B(≥ 80 years). Procedure success rate, number of endoscopic retrograde cholangiopancreatographies(ERCP), and incidence of complications were examined in both groups.RESULTS: Group B tended to include significantly more patients with peripapillary diverticulum, hypertension, hyperlipemia, cerebrovascular disease/dementia, respiratory disease/cardiac disease, and patients administered an anticoagulant or antiplatelet agent(P < 0.05). The success rate of the initial lithotomy was 88.7(94/106)%. The final lithotomy rate was 100(106/106)%. Complications due to treatment procedure occurred in 4.72(5/106)% of the patients. There was no significant difference in procedure success rate, number of ERCP, or incidence of complications between group A and group B.CONCLUSION: EPLBD can be safely performed in elderly patients, the same as in younger patients.Yuji Sakai Toshio Tsuyuguchi Harutoshi Sugiyama Reina Sasaki Dai Sakamoto Masato Nakamura Yuuto Watanabe Takao Nishikawa Shin Yasui Rintaro Mikata Osamu Yokosuka 2015World Journal of Clinical Cases2015,3,4:4
6Evaluation of prognostic factors and scoring system in colonic perforation显示文摘AIM: To study the significance of scoring systems assessing severity and prognostic factors in patients with colonic perforation. METHODS: A total of 26 patients (9 men, 17 women; mean age 72.7 ± 11.6 years) underwent emergency operation for colorectal perforation in our institution between 1993 and 2005. Several clinical factors were measured preoperatively and 24 h postoperatively. Acute physiology and chronic health evaluation Ⅱ (APACHE Ⅱ), Mannheim peritonitis index (MPI) and peritonitis index of Altona (PIA Ⅱ) scores were calculated preoperatively. RESULTS: Overall postoperative mortality rate was 23.1% (6 patients). Compared with survivors, non- survivors displayed low blood pressure, low serum protein and high serum creatinine preoperatively, and low blood pressure, low white blood cell count, low pH, low PaO2/FiO2, and high serum creatinine postoperatively. APACHE Ⅱ score was significantly lower in survivors than in non-survivors (10.4 ± 3.84 vs 19.3 ± 2.87, P = 0.00003). Non-survivors tended to display high MPI score and low PIA Ⅱ score, but no signif icant difference was identif ied. CONCLUSION: Pre- and postoperative blood pressure and serum creatinine level appear related to prognosis of colonic perforation. APACHE Ⅱ score is most associated with prognosis and scores ≥ 20 are associated with signif icantly increased mortality rate.Atsushi Horiuchi Yuji Watanabe Takashi Doi Kouichi Sato Syungo Yukumi Motohira Yoshida Yuji Yamamoto Hiroki Sugishita Kanji Kawachi 2007World Journal of Gastroenterology2007,13,23:4
7Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study)显示文摘Masato Ozaka Yuji Matsumura Hiroshi Ishii Yasushi Omuro Takao Itoi Hisatsugu Mouri Keiji Hanada Yasutoshi Kimura Iruru Maetani Yoshinobu Okabe Masaji Tani Takaaki Ikeda Susumu Hijioka Ryouhei Watanabe Shinya Ohoka Yuki Hirose Masafumi Suyama Naoto Egawa A 2012Cancer Chemotherapy and Pharmacology2012,,5:3
8Spatiotemporal changes of coxsackievirus and adenovirus receptor in rat hearts during postnatal development and in cultured cardiomyocytes of neonatal rat显示文摘Takeshi Kashimura Makoto Kodama Yuko Hotta Junichi Hosoya Kaori Yoshida Takuya Ozawa Ritsuo Watanabe Yuji Okura Kiminori Kato Haruo Hanawa Ryozo Kuwano Yoshifusa Aizawa 2004Virchows Archiv2004,,3:2
9Pretreatment AKR1B10 expression predicts the risk of hepatocellular carcinoma development after hepatitis C virus eradication显示文摘AIM To clarify the association between aldo-keto reductase family 1 member B10(AKR1B10) expression and hepatocarcinogenesis after hepatitis C virus eradication.METHODS In this study,we enrolled 303 chronic hepatitis C patients who had achieved sustained virological response(SVR) through interferon-based antiviral therapy. Pretreatment AKR1B10 expression in the liver was immunohistochemically assessed and quantified as a percentage of positive staining area by using image-analysis software. A multivariate Cox analysis was used to estimate the hazard ratios(HRs) of AKR1B10 expression for hepatocellular carcinoma(HCC) development after achieving SVR. The cumulative incidences of HCC development were evaluated using Kaplan-Meier analysis and the log-rank test.RESULTS Of the 303 chronic hepatitis C patients,153(50.5%) showed scarce hepatic AKR1B10 expression,quantified as 0%,which was similar to the expression in control normal liver tissues. However,the remaining 150 patients(49.5%) exhibited various degrees of AKR1B10 expression in the liver,with a maximal AKR1B10 expression of 73%. During the median follow-up time of 3.6 years(range 1.0-10.0 years),8/303 patients developed HCC. Multivariate analysis revealed that only high AKR1B10 expression(≥ 8%) was an independent risk factor for HCC development(HR = 15.4,95%CI: 1. 8- 1 3 2. 5,P = 0. 0 1 2). T h e 5- y e a r c u m u l a t i v e incidences of HCC development were 13.7% and 0.5% in patients with high and low AKR1B10 expression,respectively(P < 0.001). During the follow-up period after viral eradication,patients expressing high levels of AKR1B10 expressed markedly higher levels of alanine aminotransferase and α-fetoprotein than did patients exhibiting low AKR1B10 expression.CONCLUSION Chronic hepatitis C patients expressing high levels of hepatic AKR1B10 had an increased risk of HCC development even after SVR.Ayato Murata Takuya Genda Takafumi Ichida Nozomi Amano Sho Sato Hironori Tsuzura Shunsuke Sato Yutaka Narita Yoshio Kanemitsu Yuji Shimada Katsuharu Hirano Katsuyori Iijima Ryo Wada Akihito Nagahara Sumio Watanabe 2016World Journal of Gastroenterology2016,22,33:2
10CD44v6 expression is related to mesenchymal phenotype and poor prognosisin patients with colorectal cancer显示文摘Seiya Saito Hirohisa Okabe Masayuki Watanabe Takatsugu Ishimoto Masaaki Iwatsuki Yoshifumi Baba Youhei Tanaka Junji Kurashige Yuji Miyamoto Hideo Baba 2013Oncology Reports2013,,4:2
11Hyperresponsivity to Low-Dose Endotoxin during Progression to Nonalcoholic Steatohepatitis Is Regulated by Leptin-Mediated Signaling显示文摘Kento Imajo Koji Fujita Masato Yoneda Yuichi Nozaki Yuji Ogawa Yoshiyasu Shinohara Shingo Kato Hironori Mawatari Wataru Shibata Hiroshi Kitani Kenichi Ikejima Hiroyuki Kirikoshi Noriko Nakajima Satoru Saito Shiro Maeyama Sumio Watanabe Koichiro Wada Atsus 2012Cell Metabolism2012,,1:2
12The MicroRNA-21/PTEN Pathway Regulates the Sensitivity of HER2-Positive Gastric Cancer Cells to Trastuzumab显示文摘Kojiro Eto Masaaki Iwatsuki Masayuki Watanabe Satoshi Ida Takatsugu Ishimoto Shiro Iwagami Yoshifumi Baba Yasuo Sakamoto Yuji Miyamoto Naoya Yoshida Hideo Baba 2014Annals of Surgical Oncology2014,,1:2
13Extracorporeal shock wave lithotripsy of pancreatic duct stones and patient factors related to stone disintegration显示文摘Yasuyuki Karasawa Shigeyuki Kawa Yuji Aoki Yasuhide Ochi Hiroshi Unno Kendo Kiyosawa Tomofumi Watanabe 2002Journal of Gastroenterology2002,,5:2
14Synthesis of wholly alicyclic polyimides from N-silylated alicyclic diamines and alicyclic dianhydrides显示文摘Yasufumi Watanabe Yoshimasa Sakai Yuji Shibaski 0,,:1
15Mutation screening of the human Clock gene in circadian rhythm sleep disorders显示文摘Toshio Iwase Naofumi Kajimura Makoto Uchiyama Takashi Ebisawa Kimio Yoshimura Yuichi Kamei Kayo Shibui Keiko Kim Yoshinao Kudo Masaaki Katoh Tsuyoshi Watanabe Toru Nakajima Yuji Ozeki Mariko Sugishita Toru Hori Masaaki Ikeda Ryoichi Toyoshima Yuichi Inoue 2002Psychiatry Research2002,,2:1
16Conversion of degummed soybean oil to biodiesel with immobilized Candida Antarctica lipase显示文摘Yomi Watanabe Yuji Shimada Akio Sugihara 2002Journal of Molecular Catalysis B:Enzymatic2002,17,35:1
17Magnetite nanoparticle-loaded anti-HER2 immunoliposomes for combination of antibody therapy with hyperthermia显示文摘Akira Ito Yuko Kuga Hiroyuki Honda Hiroyuki Kikkawa Atsushi Horiuchi Yuji Watanabe Takeshi Kobayashi 2004Cancer Letters2004,,2:1
18Review:Enzymatic alocoholysis for bio-diesel fuel production and application of the reaction to oil processing显示文摘 Yomi Watanabe Akio Sugihara 2002Journal of Molecular Catalysis B:Enzymatic2002,17,:1
19Enzymatic alcoholysis for biodiesel fuel production and application of the reaction to oil processing显示文摘Yuji Shimada Yomi Watanabe Akio Sugihara 2002Journal of Molecular Catalysis B:Enzymatic2002,17,35:1
20Enzymatic alcoholysis for biodiesel fuel production and application of the reaction to oil processing显示文摘Yuji Shimada Yomi Watanabe Akio Sugihara Yoshio Tominaga 2002B, Enzymatic2002,,3:1
返回顶部 每页显示:
共7页 首页 上一页 第1页 下一页 末页 /7 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费